![PDF) Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial PDF) Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial](https://i1.rgstatic.net/publication/354870323_Rationale_and_design_of_the_PRevention_of_cArdiac_Dysfunction_during_Adjuvant_breast_cancer_therapy_PRADA_II_trial_a_randomized_placebo-controlled_multicenter_trial/links/61522ac0d2ebba7be75229f1/largepreview.png)
PDF) Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial
![Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline) Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline)](https://pbs.twimg.com/media/E1gxLTUVIAQ3fqE.jpg)
Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline)
![Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ... Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ...](https://pbs.twimg.com/media/E3wIBStXoAUKuLP.jpg)
Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ...
![Geeta Gulati 1, Siri Lagethon Heck 1, Anne Hansen Ree 1, Pavel Hoffmann 2, Jeanette Schulz-Menger 3, Morten W Fagerland 2, Berit Gravdehaug 1, Florian. - ppt download Geeta Gulati 1, Siri Lagethon Heck 1, Anne Hansen Ree 1, Pavel Hoffmann 2, Jeanette Schulz-Menger 3, Morten W Fagerland 2, Berit Gravdehaug 1, Florian. - ppt download](https://images.slideplayer.com/27/8955914/slides/slide_5.jpg)
Geeta Gulati 1, Siri Lagethon Heck 1, Anne Hansen Ree 1, Pavel Hoffmann 2, Jeanette Schulz-Menger 3, Morten W Fagerland 2, Berit Gravdehaug 1, Florian. - ppt download
![PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol](https://congressreport.eu/storage/app/media/ACC%202021/20210607_Steven_Deitelzweig_INT.jpg)
PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol
Prada Receive a Complimentary 4-Pc. trial set with any large spray purchase from the Prada Candy fragrance collection & Reviews - Shop All Brands - Beauty - Macy's
Prevention of cardiac dysfunction during adjuvant breast cancer therapy ( PRADA): a 2 3 2 factorial, randomized, placebo-controll
![Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21 Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21](https://pbs.twimg.com/media/E1gu7MIXsAE4ySO.png)
Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21
![Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 on Twitter: "#ACC21 #PRADA 📌 Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) 🥇best trial name 🔺RCT, Double blind 🔺 hypothesis: Long-term decline in cardiac function Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 on Twitter: "#ACC21 #PRADA 📌 Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) 🥇best trial name 🔺RCT, Double blind 🔺 hypothesis: Long-term decline in cardiac function](https://pbs.twimg.com/media/E1g3DnwXsAA7nzS.jpg)
Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 on Twitter: "#ACC21 #PRADA 📌 Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) 🥇best trial name 🔺RCT, Double blind 🔺 hypothesis: Long-term decline in cardiac function
![PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fbd375114c38c6feaefa42552dfdf20cb0070dd0/4-Table2-1.png)
PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar
![Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy ( PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol | Circulation Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy ( PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol | Circulation](https://www.ahajournals.org/cms/asset/02c15eb9-4540-4421-90b1-846feb79107c/circulationaha.121.054698.fig01.gif)